Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria
Our findings highlight the positive impact of both RSV immunization strategies-nirsevimab and RSVpreF vaccine-while underscoring the need to enhance public awareness and education to improve immunization rates. Future immunization programs must be strengthened to provide better protection for the pediatric population and reduce RSV-associated morbidity in early life.
Authors
- Wegene Borena (ORCID: https://orcid.org/0000-0001-8011-5825)
- Gisa Gerold (ORCID: https://orcid.org/0000-0002-1326-5038)
- Michaela Höck (ORCID: https://orcid.org/0000-0001-7855-0617)
- Johanna Scheiring
- Ursula Kiechl‐Kohlendorfer (ORCID: https://orcid.org/0000-0003-0433-6196)
- J. Brünner (ORCID: https://orcid.org/0000-0002-5052-7236)
- Karina Wechselberger
- Klaus Kapelari
- Ulrike Pupp Peglow
- Elisabeth Ralser
- Peter Wöckinger
- Elke Griesmaier (ORCID: https://orcid.org/0000-0002-9269-5756)
- Elisabeth D’Costa
- Verena Kaiser
Institutions
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-10-20
- DOI
- https://doi.org/10.3389/fpubh.2025.1686581
- Citations
- 2
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 2.71